SUPPLY OF
OUR PRODUCTS

 


From time to time we may experience shortages of some products and may divest or discontinue others.

For healthcare professionals who require more information about shortages, please contact:
MSD UK customer services on 01992 452094 (during public holidays please contact our UK switchboard on 01992 467272).
Please click here to download an emergency patient supply order form (for use by UK healthcare professionals only).

If you are a patient seeking information on how shortages may affect your treatment, we recommend that you consult your doctor.

For more information about our products, please call our medical information line via our switchboard on 01992 467272.

Ensuring continuity of supply of medicines and vaccines for patients is MSD’s highest priority and we have therefore taken all necessary steps to ensure supply of our products will not be negatively impacted once the UK leaves the EU. This includes building the necessary levels of stock for all medicines and products that enter the UK via the EU/EEA, in line with the Department of Health and Social Care’s request to pharmaceutical companies in August 2018. Should you have any queries on this, please use the contact details listed above.

Supply Status

Product Description Supply Status Estimated Resupply Date
  • Asmanex Twisthaler 200 micrograms Inhalation Powder 60 Dose
 Out of Stock Late June 2019
  • DIPROSALIC® Scalp Application 0.05% w/w / 2% w/w
 Out of Stock Early June 2019
  • DIPROSONE 0.05% w/w Lotion 100 mL
 Out of Stock Early July 2019
  • EMEND 125 mg powder for oral suspension
 Out of Stock Quarter 4 2019
  • MAXALT® MELT 10 mg 3 TAB
 Out of Stock Late May 2019
  • MAXALT® MELT 10 mg 6 TAB
 Out of Stock Early September 2019
  • MODURETIC 50 mg/5 mg tablets
 Out of Stock Late July 2019
  • SINEMET 12.5 mg/50 mg Tablets
 Out of Stock Mid June 2019
  • ZOELY 2.5 mg/1.5 mg film-coated Tablets
 Out of Stock 2nd Q 2020

Notifications

KEYTRUDA▼ (pembrolizumab) 50 mg vial supply arrangements

During the month of June 2019 onwards pembrolizumab will cease to be available in the 50 mg vial as lyophilised powder (50 mg powder for concentrate for solution for infusion). It will be supplied by MSD in the UK exclusively in the form of 100 mg vial (25 mg/mL concentrate for solution for infusion).

As this date is determined by the level of the demand for this presentation a precise date cannot be provided. As such we recommend that all Trusts take appropriate steps to ensure they are able to use the 100mg presentation.

Discontinuations

  • ARCOXIA® 90 mg Film-coated Tablets 5 Pack
  • ESMERON 10mg/ml Solution for Injection 10ml vial
  • INTRON A 10MIU VIAL
  • INTRON A 18MIU PEN
  • INTRON A 25MIU 2.5ML VIAL
  • INTRON A 30MIU PEN
  • INTRON A 60MIU PEN
  • MODURET-25 25/2.5 mg Tablets
  • ORGALUTRAN 0.25mg/0.5 ml solution for injection
  • PREGNYL 1500.I.U powder for solution for injection
  • PREGNYL 5000.I.U powder for solution for injection
  • PUREGON 50IU/0.5ml solution for injection
  • PUREGON 100IU/0.5ml solution for injection
  • PUREGON 300IU/0.36ml solution for injection
  • PUREGON 600IU/0.72ml solution for injection
  • PUREGON 900IU/1.08ml solution for injection

This page is intended for use by UK healthcare professionals only. Trademarks appearing on this website are owned, licensed to, promoted or distributed by Merck & Co., Inc., Kenilworth, NJ, USA, its subsidiaries or affiliates, except as noted.

Job code: GB-NON-01076Date of Preparation: May 2019